Development and Validation of a Model to Predict Posttraumatic Stress Disorder and Major Depression After a Motor Vehicle Collision

Hannah N. Ziobrowski, PhD, MPH; Chris J. Kennedy, PhD; Berk Ustun, PhD; Stacey L. House, MD, PhD; Francesca L. Beaudoin, MD, PhD; Xinming An, PhD; Donglin Zeng, PhD; Kenneth A. Bollen, PhD; Maria Petukhova, PhD; Nancy A. Sampson, BA; Victor Puac-Polanco, MD, DrPH; Sue Lee, MA; Karestan C. Koenen, PhD; Kerry J. Ressler, MD, PhD; Samuel A. McLean, MD, MPH; Ronald C. Kessler, PhD; and the AURORA Consortium

IMPORTANCE A substantial proportion of the 40 million people in the US who present to emergency departments (EDs) each year after traumatic events develop posttraumatic stress disorder (PTSD) or major depressive episode (MDE). Accurately identifying patients at high risk in the ED would facilitate the targeting of preventive interventions.

OBJECTIVES To develop and validate a prediction tool based on ED reports after a motor vehicle collision to predict PTSD or MDE 3 months later.

DESIGN, SETTING, AND PARTICIPANTS The Advancing Understanding of Recovery After Trauma (AURORA) study is a longitudinal study that examined adverse posttraumatic neuropsychiatric sequelae among patients who presented to 28 US urban EDs in the immediate aftermath of a traumatic experience. Enrollment began on September 25, 2017. The 1003 patients considered in this diagnostic/prognostic report completed 3-month assessments by January 31, 2020. Each patient received a baseline ED assessment along with follow-up self-report surveys 2 weeks, 8 weeks, and 3 months later. An ensemble machine learning method was used to predict 3-month PTSD or MDE from baseline information. Data analysis was performed from November 1, 2020, to May 31, 2021.

MAIN OUTCOMES AND MEASURES The PTSD Checklist for DSM-5 was used to assess PTSD and the Patient Reported Outcomes Measurement Information System Depression Short-Form 8b to assess MDE.

RESULTS A total of 1003 patients (median [interquartile range] age, 34.5 [24-43] years; 715 [weighted 67.9%] female; 100 [weighted 10.7%] Hispanic, 537 [weighted 52.7%] non-Hispanic Black, 324 [weighted 32.2%] non-Hispanic White, and 42 [weighted 4.4%] of non-Hispanic other race or ethnicity were included in this study. A total of 274 patients (weighted 26.6%) met criteria for 3-month PTSD or MDE. An ensemble machine learning model restricted to 30 predictors estimated in a training sample (patients from the Northeast or Midwest) had good prediction accuracy (mean [SE] area under the curve [AUC], 0.815 [0.031]) and calibration (mean [SE] integrated calibration index, 0.040 [0.002]; mean [SE] expected calibration error, 0.039 [0.002]) in an independent test sample (patients from the South). Patients in the top 30% of predicted risk accounted for 65% of all 3-month PTSD or MDE, with a mean (SE) positive predictive value of 58.2% (6.4%) among these patients at high risk. The model had good consistency across regions of the country in terms of both AUC (mean [SE], 0.789 [0.025] using the Northeast as the test sample and 0.809 [0.023] using the Midwest as the test sample) and calibration (mean [SE] integrated calibration index, 0.048 [0.003] using the Northeast as the test sample and 0.024 [0.001] using the Midwest as the test sample; mean [SE] expected calibration error, 0.034 [0.003] using the Northeast as the test sample and 0.025 [0.001] using the Midwest as the test sample). The most important predictors in terms of Shapley Additive Explanations values were symptoms of anxiety sensitivity and depressive disposition, psychological distress in the 30 days before motor vehicle collision, and peritraumatic psychosomatic symptoms.

CONCLUSIONS AND RELEVANCE The results of this study suggest that a short set of questions feasible to administer in an ED can predict 3-month PTSD or MDE with good AUC, calibration, and geographic consistency. Patients at high risk can be identified in the ED for targeting if cost-effective preventive interventions are developed.

Published online September 1, 2021.

© 2021 American Medical Association. All rights reserved.
A
dverse posttraumatic neuropsychiatric sequelae (APNS) of traumatic experiences have a substantial societal burden.1,2 Although posttraumatic stress disorder (PTSD) is the most frequently studied APNS, major depressive episode (MDE) is also common.3,4 Many people who develop these APNS are evaluated in emergency departments (EDs) shortly after their traumas,5-7 making preventive interventions possible.8 Although theory and some preliminary empirical studies suggest that certain preventive interventions might be effective for at least some of these patients,6 this area of research is underdeveloped. Even although we can pinpoint patients at high risk among the 40 million Americans who present annually to EDs after a trauma9 given that it would likely be cost-effective to provide preventive interventions only to patients at high risk.

Several previous studies10-16 attempted to develop machine learning (ML) models to predict PTSD among patients presenting to EDs after traumas. These models had good accuracy in terms of area under the receiver operating characteristic curve (AUC) predicting PTSD at 3 months (AUC, 0.79-0.85)13,14 and 12 to 15 months (AUC, 0.71)10,16 after trauma exposure and persistent PTSD (AUC, 0.75-0.89).10,12,15 However, all of these studies10-16 focused on the approximately 5% of patients with trauma who were hospitalized.17 The APNS prevalence is equally high among the 95% of patients with trauma who are discharged.18

We present the results of an analysis based on the Advancing Understanding of Recovery After Trauma (AURORA) study, a longitudinal study of the onset and course of APNS among patients presenting to an ED after a traumatic experience. We included patients discharged from the ED and those hospitalized up to 72 hours.18 We focused on motor vehicle collisions (MVCs), the most common trauma in industrialized countries19 and in AURORA. We developed a model to predict PTSD or MDE 3 months after the ED visit compared with the exclusive focus on PTSD in prior studies.10-16 Although previous studies10-16 were limited to data from patients in 1 or 2 EDs, we used data from patients in 28 EDs. We trained the model using data from patients in the Midwest and Northeast and tested the model using data from patients in EDs in the South. The predictors considered were a mix of observations (eg, patient sex and race/ethnicity), standard clinical evaluations (eg, injury site and severity and vital signs), and patient reports. Although previous studies10-16 used up to 105 predictors in their models, we aimed to develop a parsimonious model with a small number of predictors that could feasibly be administered in EDs.

Methods
Sample
AURORA enrollment began on September 25, 2017. The patients considered in this report completed 3-month assessments by January 31, 2020, at 28 urban EDs across 3 US regions (Midwest, Northeast, and South). Patients had to be 18 to 75 years of age, presenting within 72 hours of the MVC, able to speak and read English, oriented to time and place, able to comprehend the enrollment protocol, and possessing a smartphone for more than 1 year. We excluded patients with a solid organ injury of grade 1 or higher, significant hemorrhage, or need for a chest tube or operation with general anesthesia. We initially excluded patients likely to be admitted but subsequently relaxed that exclusion to include patients admitted for no more than 24 hours (as of April 4, 2018) and then for no more than 72 hours (as of December 11, 2018). A predictor variable distinguishing those admitted vs discharged was included in the analysis. All participants provided written informed consent. All data were deidentified. This study was approved by institutional review boards at each participating institution.

The study followed the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) reporting guideline20 for reporting analyses designed to develop and validate predictive models.

Patients self-reported their race by selecting one or more of the following categories: American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Pacific Islander, White, or any other race. To assess Hispanic ethnicity, patients were asked “Do you consider yourself to be of Hispanic, Latino, or Spanish origin.” Using these two variables, we created a race and ethnicity variable with 4 categories, assigned in the following order: Hispanic, non-Hispanic White, non-Hispanic Black, non-Hispanic other.

Each patient received an interviewer-administered ED assessment with self-report questions and biological sample collections described elsewhere.18 Subsequent 2-week, 8-week, and 3-month web surveys were sent by text or email for self-completion or with telephone interviewer assistance. Patients were reimbursed $60 for the ED assessment and $40 for each follow-up survey. Of the 2096 patients presenting after an MVC and completing the baseline assessment, 1003 completed all 3 follow-up surveys (eFigure in the Supplement). We focus on these 1003 patients. An inverse probability weight was used to adjust for differences in baseline measures between these 1003 patients and those in the baseline sample who missed at least 1 follow-up.21

Measures
We included 394 potential predictors that spanned 11 broad APNS risk factor domains that included MVC characteristics,
peritraumatic signs and symptoms, chronic stressors, prior life-
time traumas, past 30-day psychological distress, physical
health, past 30-day role impairment, lifetime mental disor-
ders, sociodemographic characteristics, social support, and per-
sonality. A detailed list of constructs, measures, and scoring
rules is presented in eTable 1 in the Supplement. Categorical
variables were dummy coded. Quantitative variables were stan-
dardized to a mean of 0 and variance of 1 for use in linear al-
gorithms and transformed into deciles for use in tree-based
algorithms.

Outcome
The outcome for the prediction model was self-reported PTSD
or MDE during a 30-day recall period assessed in the 3-month
survey. Posttraumatic stress disorder was assessed with the 20-
item PTSD Checklist for DSM-5.22 Of the several diagnostic
classification rules proposed for the PTSD Checklist,23,24 we
selected a conservative threshold of 38 or higher. Major de-
pressive episode was assessed with the Patient Reported Out-
comes Measurement Information System Depression Short-
Form.8b,25 Patients were classified as meeting 3-month criteria
for MDE if their scores were 30 or higher, which is 1.65 SDs
above the established general population mean based on the
conservative assumption that 5% of the general population
meets the criteria for MDE. The outcome was defined as posi-
tive if the patient met 3-month criteria for PTSD and/or MDE.
We also assessed 3-month role impairment using a modified
version of the Sheehan Disability Scale26 and the World Health
Organization Disability Assessment Schedule27 question about
days totally out of role because of health problems in the past
30 days (eTable 1 in the Supplement).

Statistical Analysis
Data analysis was performed from November 1, 2020, to May
31, 2021. Patients had to complete all 3 follow-up assess-
ments (2-week, 8-week, and 3-month assessments) because
some predictors, although referring to experiences or patient
characteristics before the MVC, were assessed in the 2-week
or 8-week surveys to reduce patient burden in the ED. We
treated the 2- and 8-week measures as if assessed at baseline.
We used mean imputation for the small amount of item-
missing data. To account for potential selection bias from
nonresponse in follow-up surveys, we used inverse probabil-
ity of response weights to adjust for the modest differences
found between baseline characteristics of patients in the analy-
sis sample and patients who did not complete at least 1
follow-up assessment.21 All analyses were performed in this
weighted data set. Weighted means of baseline variables in the
analysis sample were all within 0.1 SD of the means in the total
baseline sample (eTable 2 in the Supplement).

Substantive analysis began by comparing prevalence, co-
morbidity, and role impairments of PTSD and MDE at 3 months
using 2-sided χ² and F tests. We then developed an ML model
to predict 3-month PTSD or MDE from the baseline variables.
We used a stacked generalization method in which results were
pooled across multiple algorithms by generating an algo-


composite predicted outcome score is guaranteed in expecta-
tion to perform at least as well as the best component algo-
rithm according to a prespecified criterion, which we
defined as AUC.28 The Super Learner ensemble ML method
was used to implement this analysis.29 Consistent with
recommendations,30,31 we used a diverse set of algorithms in
the Super Learner ensemble to capture nonlinearities and in-
teractions and reduce risk of misspecification.32 These algo-
rithms included several different linear algorithms (logistic
regression, regularized regression, spline and polynomial spline
regressions, and support vector machines) and regression tree-
based algorithms (boosting and bagging ensemble trees and
bayesian additive regression trees) (eTable 3 in the Supple-
ment). Broadly similar stacking approaches have been used in
prior ED research on PTSD33 as well as in other computational
psychiatric research studies.33,34 Given the small sample size,
hyperparameter tuning was achieved by including individual
algorithms multiple times in the ensemble with different hy-
perparameter values and allowing Super Learner to weight rela-
tive importance across this range rather than using an exter-

al grid search or random search procedure.

Feature selection was performed independently in each 10-
fold cross-validation training sample. We explored 2 differ-
ent feature reduction methods, least absolute shrinkage and
selection operator (LASSO) penalized regression35 and ran-
tive importance across this range rather than using an exter-

al grid search or random search procedure.

We used a stacked generalization method in which results were
cross-validated across important segments of the population,40
was examined by estimating variation in the association of pre-
dicted risk with the observed outcome across subgroups de-

tined by several key patient sociodemographic characteris-
tics (age, sex, race/ethnicity, and income) using a robust Poisson
regression model.41 We examined predictor importance with
the model-agnostic Kernel SHAP (Shapley Additive Explana-
tions) method, which estimates the marginal contribution to
overall model accuracy of each variable in a predictor set.42 A
2-sided $P < .05$ was considered to be statistically significant.

Data management and calculations of prevalence and AUC
were performed in SAS statistical software, version 9.4 (SAS
Institute Inc).43 The Super Learner models were estimated in
Results

Prevalence of 3-Month PTSD or MDE
A total of 1003 patients (median [interquartile range] age, 34.5 [24–43] years; 715 [weighted 67.9%] female; 100 [weighted 10.7%] Hispanic, 537 [weighted 52.7%] non-Hispanic Black, 324 [weighted 32.2%] non-Hispanic White, and 42 [weighted 4.4%] of non-Hispanic other race or ethnicity were included in this study. The 3-month prevalence (SE) was 25.1% (1.4) for PTSD, 11.5% (1.0) for MDE, and 26.6% (1.4) for either (eTable 4 in the Supplement). These prevalence (SE) estimates were not markedly different from those reported retrospectively in the ED for the 30 days before MVC: 20.7% (1.3) for PTSD, 6.2% (0.8) for MDE, and 22.3% (1.3) for either. However, as noted below, our best model substantially outperformed a model using only pre-MVC PTSD and MDE to predict the 3-month outcome.

Even though 3-month MDE alone was much less common than PTSD alone (1.6% vs 15.1%; $\chi^2 = 11.1; P < .001$), the mean (SE) number of days out of role was significantly higher among patients with comorbid PTSD and MDE than among patients with PTSD alone (6.0 [0.8] vs 3.8 [0.7]; $F_1 = 4.1, P = .04$). In addition, the mean (SE) number of days out of role was substantially higher, although not significantly so, among the small number of patients with MDE alone than those with PTSD alone (7.6 [2.9] vs 3.8 [0.7]; $F_1 = 1.6; P = .21$). Broadly similar results were found for patient reports of severe role impairment (eTable 5 in the Supplement). On the basis of these results, we defined our outcome as 3-month PTSD and/or MDE rather than focusing only on PTSD. The prevalence (SE) of this outcome was comparable across the 3 regions where AURORA was performed: Northeast (n [number of patients in the region] = 352; 26.5% [percentage of those patients] [2.4]), Midwest (n = 432; 26.8% [2.2]), and South (n = 219; 26.6% [3.1]).

Model Performance
The mean (SE) AUC of the initial Super Learner model in the test sample was 0.803 (0.032) when only LASSO was used for feature selection and 0.782 (0.034) when both LASSO and ranger were used for feature selection. The AUC in the test sample was 0.663 (0.037), in comparison, when pre-MVC PTSD and MDE were the only predictors in a logistic regression model that allowed for interactions between these 2 predictors. On the basis of these results, we focused further analysis on restricted models that used only LASSO for feature selection and examined models restricted to 10 to 50 predictors. The AUC was higher in models restricted to 20, 30, or 50 predictors (mean [SE] AUC, 0.810 [0.032] for models with 20 predictors, 0.815 [0.031] for models with 30 predictors, and 0.810 [0.032] for models with 50 predictors) than the model with unrestricted predictors (mean [SE] AUC, 0.803 [0.032]) (Figure 1).

Given that the 30-predictor model had a marginally higher AUC than the others, we focused on it for further evaluation as our best model. This model had good calibration in the test sample (mean [SE] ICI, 0.040 [0.002]; mean [SE] ECE, 0.039 [0.002]). Five of the 32 algorithms in the model’s ensemble accounted for almost all the Super Learner weight: 2 of the 5 extreme gradient boosting algorithms (0.32-0.38 weights), 1 of the 3 random forest algorithms (0.18 weight), and 2 of the 11 penalized logistic regression algorithms (0.01-0.11 weights) (eTable 6 in the Supplement). The mean (SE) 30-predictor model AUC in the total test sample was 0.815 (0.031). The mean (SE) AUC was 0.709 (0.067) among patients who met criteria for PTSD and/or MDE in the 30 days before MVC and 0.791 (0.046) among patients who did not meet the pre-MVC criteria for either disorder. Fairness of the model was documented by finding that the relative risk of the outcome based on predicted probabilities from the model was comparable across test sample subgroups defined by age, sex, race/ethnicity, and income (eTable 7 in the Supplement). Geographic consistency of model performance was documented by finding comparable AUC (mean [SE] AUCs, 0.789 [0.025] using the Northeast as the test sample and 0.809 [0.023] using the Midwest as the test sample) (Figure 2) and calibration (mean [SE] integrated calibration index, 0.048 [0.003] using the Northeast as the test sample and 0.024 [0.001] using the Midwest as the test sample; mean [SE] ECE, 0.034 [0.003] using the Northeast as the test sample and 0.025 [0.001] using the Midwest as the test sample) (Figure 3) when the test sample was changed to be patients in the Northeast or Midwest.

Inspection of model sensitivity and PPV found that, despite some nonmonotonicity, patients in the top 5 predicted training sample risk ventiles, which included 29.9% of the test sample, had sensitivities between 1.7 and 2.8 times the value expected by chance, whereas remaining patients had sensitivities near (ventiles 5-10) or below (ventiles 11-20) expected

SHAP values were estimated in Python, version 3.8.5 (Python Software Foundation). The R packages used for each algorithm are listed in eTable 3 in the Supplement.
values (Table). Cumulative sensitivity across the top 5 percentiles was 65.4%, and the cumulative PPV in that range was 58.2%.

**Predictor Importance**

A total of 264 of the 394 variables (67%) in the predictor set had zero-order associations with the outcome in the total sample, including 94% to 100% of those assessing 30 days before MVC psychological distress and impairment and recent stressors; 70% to 85% of those assessing peritraumatic symptoms, social support, and personality; 50% to 60% of those assessing lifetime traumas and mental disorders and physical health; and 25% to 30% of those assessing sociodemographic and MVC characteristics (eTable 8 in the Supplement). Admission status (ie, admitted to the hospital vs discharged) was not a significant zero-order predictor (odds ratio, 1.0; 95% CI, 0.9-1.1). To examine predictor importance, we reran the best model specification (ie, 30 predictors selected by LASSO separately for linear and tree-based algorithms) in the total sample. A total of 53 predictors were selected (30 each for linear and tree-based models, with an overlap of 7 predictors), which came from 40 variables (ie, 13 were alternative transformations of the same variable) (eTable 1 in the Supplement). The 20 most important predictors accounted for 75.5% of the total mean absolute SHAP value across all predictors in the model (Figure 4). These predictors included 7 indicators of personality (6 of anxiety sensitivity and 1 of dispositional depression), 7 of peritraumatic psychosomatic symptoms, 4 of past 30-day psychological symptoms (2 depression, 1 PTSD, and 1 impairment attributable to emotional problems), and 2 of prior lifetime trauma exposure. The personality measures were among those assessed retrospectively in the 2-week follow-up survey. Replication of the Super Learner with LASSO feature selection of 30 predictors from a reduced predictor set that excluded retrospectively reported variables (ie, lifetime traumatic experiences) had a lower AUC in analyses sequentially treating...
patients in 2 regions as the training sample and those in the third region as the test sample (AUC [SE], 0.815 [0.031] using the South as the test sample, 0.789 [0.025] using the Northeast as the test sample, and 0.809 [0.023] using the Midwest as the test sample) than when the retrospectively reported variables were included (AUC [SE], 0.755 [0.035] using the South as the test sample, 0.748 [0.031] using the Northeast as the test sample, and 0.754 [0.027] using the Midwest as the test sample).

Discussion

In this study, our model’s AUC was comparable to models developed in previous ED studies to predict persistent PTSD,10-12,15 3-month PTSD,13,14 or 12- to 15-month PTSD.10,16 However, these other studies10-16 used up to 105 predictors vs 40 in our model, and many of the most important predictors in prior studies15,16 were laboratory tests that are routinely performed only for patients with trauma admitted to the hospital, which do not apply to the approximately 95% of ED patients discharged to home. The external validity of earlier models was also limited by their inclusion of only 1 or 2 EDs. In addition, whereas our model was well calibrated, only 1 previous study15 examined calibration and found it to be relatively poor.

Caution is needed in interpreting our findings regarding predictor importance because this depends on associations of predictors with each other. It is nonetheless interesting that items assessing dispositional anxiety sensitivity emerged as the most important predictors. Such measures were not included in previous studies.10-16 The other 2 most important predictor domains in our model were peritraumatic psychosomatic symptoms in the ED and psychological distress. Only 2 prior studies assessed psychological distress in the weeks13 or months14 before trauma exposure. Both found that these were important predictors. Although no prior study assessed peritraumatic psychosomatic symptoms, some assessed peritraumatic distress10,12,14,15 and dissociation14,15 and found both to be important predictors. Consistent with these prior results, we found that peritraumatic distress and dissociation were significant univariate predictors of our outcome, although they were not selected in the final model.

It is also important to recognize that the value of our model depends on unknowns about the costs and effects of preventive interventions. As noted above, this is an underdeveloped area of research.6 Determining whether the PPV of our model at a decision threshold is sufficiently high to justify implementing a targeted intervention would, at a minimum, require an evaluation of the precision recall curve and, importantly, the net benefit curve based on a formal cost-effectiveness analysis. In addition, if heterogeneity of treatment effects is found, the development of an individualized precision treatment rule would be required to evaluate the effects of our prediction model.47

Limitations

Our study has several noteworthy limitations. First, the sample included only English-speaking patients from urban EDs after

<table>
<thead>
<tr>
<th>Ventile</th>
<th>Total No. of patients</th>
<th>Within ventile Patients, %</th>
<th>Sensitivity, mean (SE)</th>
<th>PPV, mean (SE)</th>
<th>Cumulative Patients, %</th>
<th>Sensitivity, mean (SE)</th>
<th>PPV, mean (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11</td>
<td>4.7</td>
<td>13.1 (12.5)</td>
<td>74.2 (13.1)</td>
<td>4.7</td>
<td>13.1 (4.4)</td>
<td>74.2 (13.1)</td>
</tr>
<tr>
<td>2</td>
<td>9</td>
<td>4.3</td>
<td>11.4 (11.1)</td>
<td>70.4 (15.4)</td>
<td>9.0</td>
<td>24.5 (6.0)</td>
<td>72.4 (10.0)</td>
</tr>
<tr>
<td>3</td>
<td>14</td>
<td>6.5</td>
<td>12.5 (12.0)</td>
<td>51.0 (13.7)</td>
<td>15.5</td>
<td>36.9 (6.6)</td>
<td>63.4 (8.5)</td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>10.0</td>
<td>17.3 (15.6)</td>
<td>45.8 (11.4)</td>
<td>25.6</td>
<td>54.2 (6.6)</td>
<td>56.5 (7.0)</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>4.4</td>
<td>11.2 (10.9)</td>
<td>68.2 (15.4)</td>
<td>29.9</td>
<td>65.4 (6.2)</td>
<td>58.2 (6.4)</td>
</tr>
<tr>
<td>6</td>
<td>18</td>
<td>8.0</td>
<td>7.6 (7.7)</td>
<td>25.4 (10.2)</td>
<td>37.9</td>
<td>73.0 (5.8)</td>
<td>51.3 (5.7)</td>
</tr>
<tr>
<td>7</td>
<td>9</td>
<td>3.5</td>
<td>5.6 (5.8)</td>
<td>42.8 (16.6)</td>
<td>41.4</td>
<td>78.6 (5.4)</td>
<td>50.6 (5.4)</td>
</tr>
<tr>
<td>8</td>
<td>12</td>
<td>5.4</td>
<td>4.7 (4.9)</td>
<td>23.1 (12.0)</td>
<td>46.8</td>
<td>83.3 (5.0)</td>
<td>47.4 (5.1)</td>
</tr>
<tr>
<td>9</td>
<td>17</td>
<td>8.4</td>
<td>5.4 (5.6)</td>
<td>17.0 (9.5)</td>
<td>55.2</td>
<td>88.7 (4.1)</td>
<td>42.8 (4.7)</td>
</tr>
<tr>
<td>10</td>
<td>12</td>
<td>5.7</td>
<td>4.0 (4.2)</td>
<td>18.6 (11.8)</td>
<td>60.9</td>
<td>92.7 (3.2)</td>
<td>40.5 (4.4)</td>
</tr>
<tr>
<td>11</td>
<td>7</td>
<td>3.3</td>
<td>2.8 (3.0)</td>
<td>22.8 (14.9)</td>
<td>64.2</td>
<td>95.5 (2.6)</td>
<td>39.6 (4.3)</td>
</tr>
<tr>
<td>12</td>
<td>19</td>
<td>9.4</td>
<td>1.4 (1.5)</td>
<td>4.0 (4.0)</td>
<td>73.7</td>
<td>96.9 (2.2)</td>
<td>35.0 (3.9)</td>
</tr>
<tr>
<td>13</td>
<td>13</td>
<td>5.7</td>
<td>0.0</td>
<td></td>
<td>79.4</td>
<td>96.9 (2.2)</td>
<td>32.5 (3.7)</td>
</tr>
<tr>
<td>14</td>
<td>4</td>
<td>1.6</td>
<td>0.0</td>
<td></td>
<td>81.0</td>
<td>96.9 (2.2)</td>
<td>31.9 (3.6)</td>
</tr>
<tr>
<td>15</td>
<td>7</td>
<td>3.0</td>
<td>0.0</td>
<td></td>
<td>84.0</td>
<td>96.9 (2.2)</td>
<td>30.7 (3.5)</td>
</tr>
<tr>
<td>16</td>
<td>9</td>
<td>4.1</td>
<td>1.8 (1.9)</td>
<td>11.5 (11.0)</td>
<td>88.1</td>
<td>98.7 (1.3)</td>
<td>29.8 (3.4)</td>
</tr>
<tr>
<td>17</td>
<td>10</td>
<td>4.2</td>
<td>0.0</td>
<td></td>
<td>92.4</td>
<td>98.7 (1.3)</td>
<td>28.4 (3.3)</td>
</tr>
<tr>
<td>18</td>
<td>4</td>
<td>1.6</td>
<td>1.3 (1.4)</td>
<td>22.4 (20.7)</td>
<td>93.9</td>
<td>100.0</td>
<td>28.3 (3.2)</td>
</tr>
<tr>
<td>19</td>
<td>3</td>
<td>1.3</td>
<td>0.0</td>
<td></td>
<td>95.2</td>
<td>100.0</td>
<td>28.0 (3.2)</td>
</tr>
<tr>
<td>20</td>
<td>11</td>
<td>4.8</td>
<td>0.0</td>
<td></td>
<td>100.0</td>
<td>100.0</td>
<td>26.6 (3.1)</td>
</tr>
</tbody>
</table>

Abbreviations: LASSO, least absolute shrinkage and selection operator; PPV, positive predictive value.
an MVC who were followed up for 3 months. Different samples and follow-up periods might yield different results. Second, the response rate was low, raising the possibility of sample selection bias. Third, patients with pre-MVC PTSD and MDE were not excluded, although our AUC was substantially higher than in a model in which 30-day pre-MVC PTSD and MDE were the only predictors, and only 3 of our top 20 predictors were symptoms of 30-day pre-MVC PTSD or MDE. Fourth, we did not consider...
the small number of patients who were hospitalized for more than 72 hours. We also did not obtain information about outpatient treatment after ED discharge. These omissions could have reduced the external validity by excluding otherwise important baseline variables with effects on 3-month outcomes mediated by treatment. Fifth, outcome measures were based on validated self-report scales rather than clinical interviews.22,25 Sixth, some important predictors were assessed in the 2-week surveys, and overall model prediction accuracy was lower when these variables were omitted from the model. Replication in a sample that assesses these variables at baseline will be needed to determine their true importance.

Conclusion
This study found that a parsimonious model that predicts 3-month PTSD or MDE after MVC can be developed using a battery of questions that could be delivered in approximately 10 minutes. The model had good AUC and calibration and captured close to two-thirds of all patients who developed 3-month PTSD or MDE in the top 30% of the predicted risk distribution. These results suggest that if cost-effective preventive interventions are developed, identification of patients in the ED who are at high risk for treatment targeting may be possible.
the integrity of the data and the accuracy of the data analysis.

Conflict of Design: Ziobrowski, Bollen, Koenen, Resler, McLean, Kessler, Stevens, Neylan, Clifford, Jovanovic, Germaine, Rauch, Murty, McGrath, Peak, Rathlev, Joormann, Barch, Pizzagalli, Sheridan, Harte, Elliott, van Rooij.

Acquisition, analysis, or interpretation of data: Ziobrowski, Kennedy, Ustun, House, Beaudoin, An, Zeng, Peltukhova, Sampson, Puac-Polanco from Lee, Koenen, McLean, Kessler, Neylan, Clifford, Jovanovic, Linnstaedt, Rauch, Haran, Storrow, Lewandowski, Miya Jenkins, Henley, Sheikh, Jones, Punches, Lyons, McGrath, Pascual, Seamon, Datner, Chang, Pearson, Peak, Jambaulikar, Merchant, Domeier, O’Neil, Sergot, Sanchez, Bruce, Pietrzak, Joormann, Barch, Harte.

Drafting of the manuscript: Ziobrowski, McLean, Kessler, Haran, Rathlev, Joormann, Elliott.

Critical revision of the manuscript for important intellectual content: Ziobrowski, Kennedy, Ustun, House, Beaudoin, An, Zeng, Bollen, Peltukhova, Sampson, Puac-Polanco from Lee, Koenen, McLean, Kessler, Stevens, Neylan, Clifford, Jovanovic, Linnstaedt, Germaine, Rauch, Storrow, Lewandowski, Miya Jenkins, Henley, Sheikh, Jones, Punches, Lyons, Murty, McGrath, Pascual, Seamon, Datner, Chang, Pearson, Peak, Jambaulikar, Merchant, Domeier, Rathlev, O’Neil, Sergot, Sanchez, Bruce, Pietrzak, Joormann, Barch, Pizzagalli, Sheridan, Harte, Elliott, van Rooij.


Obtained funding: Bollen, Koenen, McLean, Kessler, Neylan, Germaine.

Administrative, technical, or material support: Ziobrowski, Beaudoin, Puac-Polanco, Resler, McLean, Stevens, Neylan, Clifford, Linnstaedt, Germaine, Storrow, Lewandowski, Henley, Sheikh, Punches, Murty, Datner, Chang, Pearson, Peak, Jambaulikar, Rathlev, O’Neil, Sergot, Sanchez, Bruce, Pietrzak, Barch, Pizzagalli, Harte, van Rooij.


Conflict of Interest Disclosures: Dr Ziobrowski reported receiving grants from National Institute of Mental Health (NIMH) during the conduct of the study. Dr An reported receiving grants from the NIMH, US Army Medical Research and Material Command, The One Mind Foundation, and The Mayday Fund and nonfinancial technical support in collecting and processing smartphone and swatch data from Verily Life Science and Mindstrong Health during the conduct of the study. Dr Sampson reported receiving grants from the NIMH during the conduct of the study. Dr Lee reported receiving grants from the NIMH during the conduct of the study. Dr Resler reported receiving grants from Takeda and Brainisway and personal fees from Janssen, Verily, Allo Neuroscience, and Bioxcel outside the submitted work. Dr McLean reported receiving grants from the NIMH, Mindstrong Health, and Verily Life Sciences during the conduct of the study. Dr Kessler reported receiving grants from the NIMH, receiving consulting fees from DataStat Inc and Sage Pharmaceuticals, and owning stock in Mirah, PYM, and Roga Sciences during the conduct of the study. Dr Clifford reported receiving grants from University of North Carolina as a subcontract on the parent AURORA grant funding during the conduct of the study and in the past 3 years has received research funding from the National Science Foundation, National Institutes of Health (NIH), and LifeBell AI and unrestricted donations from AliveCor, Amazon Research, Center for Discovery, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, Gates Foundation, Google, One Mind Foundation, and Samsung Research. Dr Clifford also has financial interest in AliveCor and receives unrestricted funding from the company and is the chief technical officer of MindChild Medical and the chief security officer of LifeBell AI and has ownership in both companies. Dr Jovanovic reported receiving grants from NIH during the conduct of the study and outside the submitted work. Dr Germaine reported serving on the Scientific Advisory Board for Sage Bioworks for which she receives a small honorarium. Dr Rauch reported receiving grants from NIH during the conduct of the study and grants from NIH, personal fees from Society of Biological Psychiatry, royalties from Oxford University Press and APP, a per diem for serving on the NVEF board for the Veterans Affairs, funds for board service from Community Psychiatry, including equity outside the submitted work, and having leadership roles on boards or councils for Society of Biological Psychiatry, Anxiety and Depression Association of America, and National Network of Depression Centers outside the submitted work. Dr Storrow reported receiving grants from NIH during the conduct of the study. Dr Sheikh reported receiving grants from Florida Medical Malpractice Joint Underwriter’s Association, Substance Abuse and Mental Health Services Administration, Florida Blue Foundation, and NIH/National Institute on Aging-funded Jacksonville Aging Studies Center outside the submitted work. Dr Jones reported receiving grants from NIH during the conduct of the study and grants from Vapotherm Inc, Janssen, AstraZeneca, and Hologic Inc outside the submitted work. Dr Lyons reported receiving grants from NIH during the conduct of the study. Dr Pascual reported receiving grants from Grifols SA and personal fees for expert testimony outside the submitted work. Dr Chang reported receiving grants from NIH during the conduct of the study and personal fees from Roche and grants from Abbott, Ortho Clinical Diagnostics, and Siemens outside the submitted work. Dr Pearson reported receiving grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases during the conduct of the study. Dr Bruce reported receiving grants from NIH during the conduct of the study. Dr Joormann reported receiving personal fees from Janssen Pharmaceuticals outside the submitted work. Dr Barch reported receiving grants from National Institute of Drug Abuse and NIH during the conduct of the study. Dr Pizzagalli reported receiving grants from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathways, Concert Pharmaceuticals, Engrail Therapeutics, Neurocine Biosciences, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, and Alkermes, receiving grants from Millennium Pharmaceuticals, NIMH, Brain and Behavior Research Foundation, and Dana Foundation, and having stock options in BlackThorn Therapeutics outside the submitted work. Dr Harte reported receiving grants from Aptinyx, Arbor Medical Innovations, and NIH personal fees and personal fees from Eli Lilly outside the submitted work. Dr Elliott reported receiving personal fees from Orafacial Therapeutics Foundation outside the submitted work. No other disclosures were reported.

Funding/Support: Advancing Understanding of Recovery After Trauma (AURORA) is supported by grant U01MH110925 from the NIMH, the US Army Medical Research and Material Command, the One Mind Foundation, and The Mayday Fund. Verily Life Sciences and Mindstrong Health provided some of the hardware and software used to perform study assessments. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

© 2021 American Medical Association. All rights reserved.
Prediction of Posttraumatic Stress Disorder and Depression After a Motor Vehicle Collision

Original Investigation Research

prognosis or diagnosis (TRIPOD): the TRIPOD multivariable prediction model for individual

worldwide: results from the World Mental Health epidemiology of traumatic event exposure

do:10.1038/s41591-020-0951-z


